SQLite Web: event_store.db

Update row sig_6389499943f6 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","company":"Wave Life Sciences Ltd.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_01d6e296fda6a51b","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:13:06.752888+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt","source_event_id":"evt_e5d837797ecc","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"5d5c999048b1dcf0","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-16","2025-06-23"],"entities":[{"asset_class":"equity","name":"Wave Life Sciences Ltd.","relevance":"high","symbol":"WVE","type":"issuer"},{"asset_class":"equity","name":"Wave-Singapore","relevance":"high","symbol":"","type":"corporate entity"},{"asset_class":"equity","name":"Wave Life Sciences, Inc. (Wave-Delaware)","relevance":"high","symbol":"","type":"corporate entity"},{"asset_class":"other","name":"Implementation Agreement","relevance":"high","symbol":"","type":"agreement"},{"asset_class":"other","name":"Scheme of Arrangement","relevance":"high","symbol":"","type":"transaction mechanism"},{"asset_class":"other","name":"High Court of the Republic of Singapore","relevance":"medium","symbol":"","type":"court"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"merger_acquisition","information_gaps":["What changed vs prior known state is not provided in the signal; only the current 8-K content is available here.","The filing\u2019s specific SEC item(s) and any additional material items are not included in the cleaned text (material_items list is empty).","No financial implications (e.g., costs, tax effects, expected timing beyond court/shareholder approvals) are stated in the provided text.","The excerpt is truncated near the end (\u201csu\u201d), so any remaining details about participants/solicitation are not fully captured."],"key_facts":["On April 15, 2026, Wave Life Sciences Ltd. announced it decided to restructure its corporate group so the parent company would be a Delaware corporation (the \u201cRedomiciliation\u201d).","Boards of directors of Wave-Singapore and Wave-Delaware approved entry into an Implementation Agreement on April 15, 2026.","The Implementation Agreement provides for a Singapore-law statutory procedure known as a scheme of arrangement, subject to approval of Wave-Singapore shareholders and the High Court of the Republic of Singapore.","Under the Scheme of Arrangement, all issued Wave-Singapore ordinary shares as of immediately prior to the effective time will be exchanged on a one-for-one basis for newly issued shares of Wave-Delaware common stock.","After the Scheme of Arrangement, Wave-Singapore will become a subsidiary of Wave-Delaware.","Wave-Singapore expects to file a preliminary proxy statement on Schedule 14A with the SEC on April 15, 2026 to provide additional information.","The Implementation Agreement is filed as Exhibit 2.1 to the Current Report on Form 8-K.","Wave-Singapore issued a press release on April 15, 2026; it is attached as Exhibit 99.1 and incorporated by reference."],"numeric_claims":[{"label":"share exchange ratio","value":"one-for-one"},{"label":"execution date of Implementation Agreement","value":"2026-04-15"}],"primary_claim":"Wave Life Sciences Ltd. (Wave-Singapore) entered into an Implementation Agreement to complete a redomiciliation via a Singapore scheme of arrangement, exchanging Wave-Singapore ordinary shares one-for-one for newly issued Wave-Delaware common stock and making Wave-Singapore a subsidiary of Wave-Delaware.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Wave Life Sciences Ltd. filed a Form 8-K on April 15, 2026 announcing a corporate group restructure (redomiciliation) to make the parent company a Delaware corporation. The filing describes an Implementation Agreement for a Singapore scheme of arrangement and notes that additional details will be in a Schedule 14A preliminary proxy statement.","topics":["redomiciliation","scheme of arrangement","Implementation Agreement","share exchange","proxy statement (Schedule 14A)","Exhibit 2.1","Exhibit 99.1"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Wave Life Sciences Ltd. \u00b7 Filed 20260415","ticker":"WVE","tickers":["WVE"],"title":"WVE filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157003.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel